ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cost-effectiveness of cancer screening and overall survival benefit.Translational cancer research · 2026Article
- Liquid biopsies across the cancer care continuum.Nature medicine · 2025Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
backgroundCancer remains a significant global health challenge, particularly for subpopulations with risk factors including genetic predisposition, comorbidities, and lifestyle, along with age. The Galleri multicancer early detection (MCED) test is projected to be cost-effective for individuals ≥50 years of age. However, its potential value in subpopulations with elevated cancer risk remains underexplored. This study evaluates the cost-effectiveness (CE) of the Galleri test combined with usual care screening in subpopulations with varying cancer risk, including impact on overall cancer burden.
methodsA hybrid cohort-level model evaluated US subpopulations of 50 to 79 years of age with additional risk factors, incorporating updated cancer incidence rates and excess competing mortality. The model estimated lifetime economic and clinical outcomes of annual MCED testing. Analyses focused on individuals with obesity, diabetes, smoking history, heavy alcohol use, genetic predispositions, immunocompromising conditions, family history, and cancer survivors.
resultsThe Galleri test was cost-effective across all specified subpopulations, with incremental CE ratios (ICER) below the general population benchmark of $66,043 per quality-adjusted life-year. Subpopulations with higher cancer incidence, such as those with hereditary cancer syndromes, showed lower ICERs, underscoring the CE in targeted screening. However, targeted approaches address a smaller fraction of the population burden. These findings depend on translating overall MCED test performance to higher-risk groups. Sensitivity analyses confirmed the robustness of these findings, emphasizing MCED's potential to reduce late-stage cancer burden.
conclusionsPrioritizing higher-risk groups yields more favorable CE but affects a smaller overall population burden. IMPACT: This study compares how MCED testing strategies affect CE and population health benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.